MedTrace Logo

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00033228 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2011-05-12

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 500 ug

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 1000 ug

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, 1500 ug

Sponsors & Collaborators

  • Mannkind Corporation

    lead INDUSTRY

Principal Investigators

  • Chief Scientific Officer · Mannkind Corporation

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2003-03-31
Completion
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00033228 on ClinicalTrials.gov